Reports and Briefs on Therapy Area in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Product Profiles: Insomnia - Orexin receptor antagonists may yet refresh the insomnia market

In-depth analysis of key prescription brands and pipeline agents for the treatment of insomnia. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
19 Dec 2011 $6400
Buy
Report
Report

Product Profiles: Osteoporosis - Novel candidates offer the greatest potential

In depth analysis of key brands and pipeline agents indicated for the treatment of osteoporosis. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
14 Dec 2011 $6400
Buy
Report
Report

Market and Product Forecasts: COPD – Growth expected despite untapped market potential

With significant new products, including Arcapta Neohaler and Daliresp, and numerous pipeline candidates forecast to launch, the COPD market is changing. Datamonitor’s patient based forecast estimates a growing market, despite generic erosion.

Published By Datamonitor
28 Nov 2011 $6400
Buy
Report
Report

Product Profiles: Psoriasis – Novel therapies raise the bar for biologics

This report analyzes key marketed and pipeline agents for psoriasis, including the current market dynamics of topical, oral and biologic products, key lifecycle management strategies, as well as clinical trial data from 2011 dermatology conferences.

Published By Datamonitor
23 Nov 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor

Datamonitor forecasts sales of leading antidyslipidemic brands and pipeline products. Coverage: US, Japan, France, Germany, Italy, Spain, and the UK

Published By Datamonitor
23 Nov 2011 $6400
Buy
Report
Report

Market and Product Forecast: Osteoporosis - Prolia and odanacatib to restore growth in the market

Osteoporosis drug forecast sales trends up to 2020 across the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK). The analysis is designed to understand the future dynamics of the osteoporosis prescription market.

Published By Datamonitor
01 Nov 2011 $6400
Buy
Report
Report

Prescribing Influences: Type 2 Diabetes – Opportunities in type 2 diabetes for drugs with both safety and efficacy

Datamonitor reports physician perceptions and key opinion leader insight into unmet needs in type 2 diabetes, as well as how well marketed and late-stage pipeline classes perform in key influencing criteria for prescribing choice.

Published By Datamonitor
29 Sep 2011 $2800
Buy
Report
Report

Market and Product Forecasts: Neuropathic Pain - Targeting underserved indications drives market growth

This report assesses the current and future neuropathic market accounting for the latest market events. The analysis is designed to understand the future dynamics of the neuropathic pain drug market.

Published By Datamonitor
14 Sep 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market

Focusing on disease-modifying drugs, Datamonitor uses a patient-based approach to size the seven major rheumatoid arthritis markets from 2010 to 2020. Robust epidemiology forecasts, survey data and opinion leader discussions validate key assumptions.

Published By Datamonitor
08 Sep 2011 $6400
Buy
Report
Report

Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

Analysis of current market dynamics for the treatment of prostate cancer. The report assesses comparator therapies for prostate cancer, identifies key strategies for drug development, and analyzes commercial and clinical potential of pipeline drugs.

Published By Datamonitor
02 Sep 2011 $6400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.